Cholangiocarcinoma: classification and staging

2018 ◽  
pp. 55-64
Author(s):  
A. I. Shchegolev ◽  
U. N. Tumanova ◽  
G. G. Karmazanovsky ◽  
O. D. Mishnev
Keyword(s):  
Bile Ducts ◽  
Tnm Classification ◽  
Term Survival ◽  
Long Term Survival ◽  
Treatment Methods ◽  
Disease Prognosis ◽  
8Th Edition

The main classifications of cholangiocarcinoma (CC) are currently the TNM classification, as well as the Bismuth–Corlette and MSKCC classifications. The criteria of T, N and M categories and characteristics of the stages of cholangiocarcinoma of the proximal and distal bile ducts, which are specified in the modern 8th edition of the international TNM classification, are presented. TNM classification is the most common for the development of treatment methods and the determination of disease prognosis. The Bismuth–Corlette classification, which characterizes the CC of the bile ducts in the region of the gate of the liver, is used to determine the type and volume of surgery. MSKCC classification of the CC of proximal bile ducts is designed to assess the prognosis of resectability, the risk of metastases and long-term survival of patients.

scholarly journals Validation of the 8th lung cancer TNM classification and clinical staging system in a German cohort of surgically resected patients

2020 ◽  
Vol 5 (1-2) ◽  
pp. 1-9
Author(s):  
Samantha Taber ◽  
Joachim Pfannschmidt
Keyword(s):  
Lung Cancer ◽  
Tnm Classification ◽  
Clinical Staging ◽  
Term Survival ◽  
Long Term Survival ◽  
7Th Edition ◽  
Tumor Stages ◽  
8Th Edition

AbstractObjectivesThe updated 8th edition of the tumor, node, metastases (TNM) classification system for non-small cell lung cancer (NSCLC) attempts to improve on the previous 7th edition in predicting outcomes and guiding management decisions. This study sought to determine whether the 8th edition was more accurate in predicting long-term survival in a European population of surgically treated NSCLC patients.MethodsWe scanned the archives of the Heckeshorn Lung Clinic for patients with preoperative clinical stages of IIIA or lower (based on the 7th edition), who received surgery for NSCLC between 2009 and 2014. We used pathologists’ reports and data on tumor size and location to reassign tumor stages according to the 8th edition. We then analyzed stage specific survival and compared the accuracy of the two systems in predicting long-term survival. We excluded patients with neoadjuvant treatment, incomplete follow-up data, tumor histologies other than NSCLC, or death within 30 days of surgery.ResultsThe final analysis included 1,013 patients. Overall five-year survival was 47.3%. The median overall survival (OS) was 63 months (range 1–222), and the median disease-free survival (DFS) was 50 months (0–122). The median follow-up time for non-censored patients was 84 months (range 60–122).ConclusionsWe found significant survival differences between the newly defined stages 1A1, 1A2 and 1A3 (previously 1A). We also found that the 8th edition of TMN classification was a significantly better predictor of long-term survival, compared to the 7th edition.

Determination of a predictive cutoff value of NT-proBNP testing for long-term survival in ED patients with acute heart failure

2013 ◽  
Vol 31 (12) ◽  
pp. 1634-1637 ◽  
Author(s):  
Yalcin Velibey ◽  
Yalcin Golcuk ◽  
Burcu Golcuk ◽  
Deniz Oray ◽  
Ozge Duman Atilla ◽  
...  
Keyword(s):  
Heart Failure ◽  
Acute Heart Failure ◽  
Term Survival ◽  
Cutoff Value ◽  
Long Term Survival

Impact of intraoperative staging of gastric cancer on long-term survival.

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 302-302
Author(s):  
Keisuke Koumori ◽  
Kazuki Kano ◽  
Hayato Watanabe ◽  
Yota Shimoda ◽  
Hirohito Fujikawa ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Negative Impact ◽  
Tnm Classification ◽  
Clinical Stage ◽  
Term Survival ◽  
Long Term Survival ◽  
Preoperative Stage ◽  
The Impact ◽  
The Relationship

302 Background: The preoperative stage and intraoperative stage of gastric cancer were unified as the clinical stage in the 8th edition of the TNM classification (UICC). Although there are some reports about the relationship between preoperative stage and prognosis, the relationship between intraoperative stage and prognosis remains unclear. The aim of this study was to clarify the impact of intraoperative diagnosis and staging on long-term survival. Methods: Overall survivals were examined in 915 patients who underwent curative resection for gastric adenocarcinoma between April 2011 and March 2019 in our hospital. Results: The median age of the patients was 69 years (27-90 years), including 585 male and 330 female. The median follow-up period was 33.6 months (0.1-86.7 months). The number of the patients according to intraoperative stage were 641(70.1 %) in stageI, 15(1.6%) in stageIIA, 135(14.8%) in stageIIB, 111(12.1%) in stageIII, 12(1.3%) in stageIVA and 1(0.1%) in stageIVB. The hazard ratios of intraoperative stage for overall survival were as follows (ref: StageI); StageIIA, 6.990 (95% CI: 2.473-19.760, p < 0.001), StageIIB, 2.234 (95% CI: 1.220-4.092, p = 0.009), StageIII, 4.091 (95% CI: 2.416-6.928, p < 0.001), StageIVA, 6.061 (95% CI: 2.150-17.080, p < 0.001), StageIVB, 14.92 (95% CI: 2.035-109.3, p = 0.008). Conclusions: The survival of intraoperative StageIIA was poorer than StageIIB/III. Intraoperative positive lymph node metastasis could be negative impact of survival, even if tumor invasion was T1 or T2.

scholarly journals IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival

2013 ◽  
Vol 15 (4) ◽  
pp. 469-479 ◽  
Author(s):  
S. Leu ◽  
S. von Felten ◽  
S. Frank ◽  
E. Vassella ◽  
I. Vajtai ◽  
...  
Keyword(s):  
Strong Predictor ◽  
Molecular Classification ◽  
Low Grade Glioma ◽  
Low Grade ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer

2020 ◽  
Vol 18 (8) ◽  
pp. 1096-1104
Author(s):  
Min Huang ◽  
Joyce O’Shaughnessy ◽  
Jing Zhao ◽  
Amin Haiderali ◽  
Javier Cortes ◽  
...  
Keyword(s):  
Triple Negative ◽  
Pathologic Complete Response ◽  
Complete Response ◽  
Sensitivity Analyses ◽  
Coefficient Of Determination ◽  
Survival Outcomes ◽  
Term Survival ◽  
Long Term Survival

Background: Pathologic complete response (pCR) is a common efficacy endpoint in neoadjuvant therapy trials for triple-negative breast cancer (TNBC). Previous studies have shown that pCR is strongly associated with improved long-term survival outcomes, including event-free survival (EFS) and overall survival (OS). However, the trial-level associations between treatment effect on pCR and long-term survival outcomes are not well established. This study sought to evaluate these associations by incorporating more recent clinical trials in TNBC. Methods: A literature review identified published randomized controlled trials (RCTs) of neoadjuvant therapy for TNBC that reported results for both pCR and EFS/OS. Meta-regression models were performed to evaluate the association of treatment effect on pCR and EFS/OS. Sensitivity analyses were conducted to assess the impact of divergent study designs. Results: Ten comparisons from 8 RCTs (N=2,478 patients) were identified from the literature review. The log (odds ratio) of pCR was a significant predictor of the log (hazard ratio) of EFS (P=.003), with a coefficient of determination of 0.68 (95% CI, 0.41–0.95). There was a weaker association between pCR and OS (P=.18), with a coefficient of determination of 0.24 (95% CI, 0.01–0.77). Consistent results were found in the exploratory analysis and sensitivity analyses. Conclusions: This is the first study that has shown a trial-level association between pCR and survival outcomes in TNBC. By incorporating the most up-to-date RCTs, this study showed a significant trial-level association between pCR and EFS. A positive association between pCR and OS was also recorded.

Novel molecular classification of colorectal cancer and correlation with long-term survival.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e15514-e15514
Author(s):  
Fayaz Hussain Mangi ◽  
Tanweer Ahmed Shaikh ◽  
Daniel Soria ◽  
Jawaid Naeem Qureshi ◽  
Ikram Uddin Ujjan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Median Survival ◽  
Clinical Information ◽  
Molecular Classification ◽  
Limited Information ◽  
Ki 67 ◽  
Term Survival ◽  
Long Term Survival

e15514 Background: Colorectal cancer (CRC) is a heterogeneous disease, however there is limited information available regarding molecular classification and correlation with long term clinical outcome. Methods: Over the period of 11 years (2008 to 2018) totals 435 patients of colorectal cancer were reported and their tumour blocks and complete set of clinical information was available for 201 patients. Immunohistochemistry was done for ER, PR, HER 2-neu, Ki-67, Bcl-2, E-Cadherin, P53, CEA, EGFR, and VEGF. PDL1, CDX-2 and CK 20. The biological pattern characterized by partitioned clustering method as described using R software. Survival analysis was done by using Kaplan Meier method. Results: There were 201 patients including 54.7% male and females were 45.3 %. Median survival was 28 months. Cluster analysis showed four novel clusters (Table), with major difference based on Ki67, CDX2 and p53. These classes showed difference in median survival, where common class 1 showed higher survival while common cluster 4 showed poor survival. Conclusions: There are at least four distinct molecular classes of colorectal cancer which can be potentially utilized in clinical practice. Pattern of Novel molecular classification of colorectal cancer and correlation with long term survival.[Table: see text]

Human thymic epithelial cells maintain long-term survival of clonogenic myeloid and erythroid progenitor cells in vitro

2000 ◽  
Vol 111 (1) ◽  
pp. 363-370 ◽  
Author(s):  
Katsuto Takenaka ◽  
Mine Harada ◽  
Tomoaki Fujisaki ◽  
Koji Nagafuji ◽  
Shinichi Mizuno ◽  
...  
Keyword(s):  
Epithelial Cells ◽  
Progenitor Cells ◽  
Thymic Epithelial Cells ◽  
Erythroid Progenitor ◽  
Term Survival ◽  
Long Term Survival ◽  
Erythroid Progenitor Cells
Sign in / Sign up

Export Citation Format

Share Document